PTPRT and neoplasm: Interestingly, stratified survival analysis by tumor origin revealed preserved prognostic advantage of PTPRT mutations in NSCLC/SKCM/BRCA (Log-rank test, P = 0.012, Figure 6E), but not in other subtypes.